BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
These are the Fastest Italian Sports Cars - 2Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- 3BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- 4New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- 5Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Abbott issues US device correction for some glucose monitors over faulty readings risk
- We may have less control over how long we live than previously thought
- Disability rights activist and author Alice Wong dies at 51
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- Overseeing Individual budgets Successfully
- Exploring Asia’s Realm of Flying Snakes
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
